Kronos Bio Stock Fundamentals
| KRON Stock | USD 0.94 0.02 2.17% |
Kronos Bio fundamentals help investors to digest information that contributes to Kronos Bio's financial success or failures. It also enables traders to predict the movement of Kronos Stock. The fundamental analysis module provides a way to measure Kronos Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kronos Bio stock.
At this time, Kronos Bio's Income Tax Expense is very stable compared to the past year. As of the 15th of March 2025, Non Operating Income Net Other is likely to grow to about 4.7 M, while Depreciation And Amortization is likely to drop about 1.8 M. Kronos | Select Account or Indicator |
Kronos Bio Company Return On Asset Analysis
Kronos Bio's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Kronos Bio Return On Asset | -0.25 |
Most of Kronos Bio's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kronos Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Kronos Total Assets
Total Assets |
|
Based on the latest financial disclosure, Kronos Bio has a Return On Asset of -0.2513. This is 97.13% lower than that of the Biotechnology sector and 98.94% lower than that of the Health Care industry. The return on asset for all United States stocks is 79.5% higher than that of the company.
Kronos Bio Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kronos Bio's current stock value. Our valuation model uses many indicators to compare Kronos Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kronos Bio competition to find correlations between indicators driving Kronos Bio's intrinsic value. More Info.Kronos Bio is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Kronos Bio's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kronos Bio's earnings, one of the primary drivers of an investment's value.Kronos Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kronos Bio's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kronos Bio could also be used in its relative valuation, which is a method of valuing Kronos Bio by comparing valuation metrics of similar companies.Kronos Bio is currently under evaluation in return on asset category among its peers.
Kronos Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Kronos Bio from analyzing Kronos Bio's financial statements. These drivers represent accounts that assess Kronos Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Kronos Bio's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.4B | 1.6B | 744.1M | 91.0M | 104.7M | 99.5M | |
| Enterprise Value | 1.4B | 1.2B | 438.4M | 46.2M | 53.1M | 50.4M |
Kronos Fundamentals
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (6.63) % | ||||
| Current Valuation | (41.92 M) | ||||
| Shares Outstanding | 60.34 M | ||||
| Shares Owned By Insiders | 26.88 % | ||||
| Shares Owned By Institutions | 32.71 % | ||||
| Number Of Shares Shorted | 917.99 K | ||||
| Price To Book | 0.50 X | ||||
| Price To Sales | 5.75 X | ||||
| Revenue | 6.29 M | ||||
| Gross Profit | 9.86 M | ||||
| EBITDA | (119.69 M) | ||||
| Net Income | (112.67 M) | ||||
| Cash And Equivalents | 267.89 M | ||||
| Cash Per Share | 4.72 X | ||||
| Total Debt | 28.27 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 15.07 X | ||||
| Book Value Per Share | 1.84 X | ||||
| Cash Flow From Operations | (78.58 M) | ||||
| Short Ratio | 4.59 X | ||||
| Earnings Per Share | (1.43) X | ||||
| Target Price | 2.25 | ||||
| Number Of Employees | 62 | ||||
| Beta | 1.8 | ||||
| Market Capitalization | 56.72 M | ||||
| Total Asset | 213.28 M | ||||
| Retained Earnings | (508.86 M) | ||||
| Working Capital | 154.08 M | ||||
| Net Asset | 213.28 M |
About Kronos Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kronos Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kronos Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kronos Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 11 M | 6.1 M | |
| Total Revenue | 7.2 M | 7.6 M | |
| Cost Of Revenue | 5.7 M | 4.2 M | |
| Stock Based Compensation To Revenue | 3.58 | 3.18 | |
| Sales General And Administrative To Revenue | 5.97 | 5.31 | |
| Research And Ddevelopement To Revenue | 12.36 | 10.99 | |
| Capex To Revenue | 0.10 | 0.09 | |
| Revenue Per Share | 0.10 | 0.09 | |
| Ebit Per Revenue | (17.44) | (18.31) |
Pair Trading with Kronos Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kronos Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kronos Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with Kronos Stock
The ability to find closely correlated positions to Kronos Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kronos Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kronos Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kronos Bio to buy it.
The correlation of Kronos Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kronos Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kronos Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kronos Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Kronos Bio Piotroski F Score and Kronos Bio Altman Z Score analysis. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share | Quarterly Revenue Growth 1.585 | Return On Assets | Return On Equity |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.